S-1 · primary offering
Proposed maximum
Shares registered
- Filed
- Effective
ALLR$1.06+8.42%
Allarity Therapeutics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$16.89M
Float & O/S:
Inst Own:
DilutionScan read 44 of Allarity Therapeutics, Inc.'s SEC filings and found 2 warrant series, 1 convertible, 1 ATM program, 1 equity line, 6 shelf registrations, 3 S-1 registrations and 3 completed offerings on file for ALLR. The latest dilution event on file is a registration statement on Apr 24, 2026. Analysis updated Nov 2, 2026.
Signal8 Summary
ALLR
Clinical-stage biotech with massive dilution
Snapshot
Allarity is a clinical-stage biotech focused on cancer treatments. It is a tiny micro-cap with negligible revenue of $320K in FY 2025 and a net loss of $11.2M. The business burns about $15M a year to fund operations.
What's Happening Right Now
- : The company secured $20 million in promissory note financing and a $6 million equity line, extending its cash runway into mid-2028.
- : Allarity began a Phase 3 manufacturing campaign for stenoparib, aiming to complete it by Q3 2026 to support a pivotal trial in advanced ovarian cancer.
- : Allarity received a Notice of Allowance from the USPTO for a patent covering its stenoparib companion diagnostic, potentially securing exclusivity into 2039.
Raise routes on file: effective shelf · latest dilution event 193 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Apr 24, 2026 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Completed
S-1 · primary offering
Proposed maximum
Shares registered
- Filed
- Effective
S-1 registration
Issued 2023
Proposed maximum
Shares registered
- Filed
- Effective
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2024
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
Equity line
Issued 2026
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
S-3 shelf registration
Issued 2023
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2023
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your ALLR trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
